secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055630
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies
--------------------------------------------------------------------------------

- Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.
- GAAP R&D expenses $29.9M, including $5.0M milestone to Aurigene for KAT6 program.
- Completed enrollment in 60-patient Phase 1b/2 studies of palazestrant + ribociclib and + palbociclib.
- New clinical data for palazestrant+ribociclib at ESMO Breast Cancer May 15-17; investor call May 15.
- Expect IND for OP-3136 (KAT6 inhibitor) in late 2024; plan Phase 1b/2 palazestrant+everolimus in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/0000950170-24-055630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/olma-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer